ABOUT

SCIENCE

PATIENTS

News

16
2022-05
Recent Progresses in Gene Therapy Presented by Vitalgen BioPharma at the ASGCT Annual Meeting
The 25th Annual Meeting of American Society of Gene & Cell Therapy (ASGCT) will be held on May 16-19, 2022 in Washington, D.C., USA. Shanghai Vitalgen BioPharma Co., Ltd. have submitted two poster presentations describing recent research progresses in collaboration with the Institute of Zoology, Chinese Academy of Science, making its first appearance at the ASGCT Annual Meeting.
20
2022-04
VGB-R04 Obtained the Tacit Approval for Clinical Trials
On April 20, 2022, according to the official website of the Center for Drug Evaluation of National Medical Products Administration (NMPA), VGB-R04 injection (hereinafter referred to as "the product"), the first gene replacement therapy drug independently developed by Shanghai Vitalgen BioPharma Co., Ltd. (hereinafter referred to as "Vitalgen"), was officially granted a tacit approval for clinical trials by NMPA. The product is intended for hemophilia B caused by congenital deficiency of the coagulation factor FIX.
14
2021-12
The first in vivo gene therapy product developed in China for hemophilia B granted ODD by FDA 
(Eastern Standard Time, December 14, 2021),VGB-R04 (an Adeno-Associated Viral Vector Delivering Human FIX Padua gene), the first drug candidate independently developed by Shanghai Vitalgen BioPharma Co., Ltd., has been granted Orphan Drug Designation (ODD) by the Office of Orphan Drug Product Development of FDA in the United States.
16
2021-10
Vitalgen closed 200 million RMB Series A+ funding round
(Shanghai, China, October 16, 2021),Shanghai Vitalgen BioPharma Co., Ltd. has raised 200 million RMB Series A+ funding round. The financing is led by Hillhouse. Other new and existing investors include Cenova Capital, Lingang Life Blue Bay Capital. IDG and Loyal Valley Capital.  
25
2021-05
Vitalgen closed 300 million RMB Series A funding round
(Shanghai, China, May 25, 2021), Shanghai Vitalgen BioPharma Co., Ltd. has raised 300 million RMB in its Series A funding round. The financing is led by Loyal Valley Capital, with participation from Jifeng Ventures and IDG.
23
2020-06
Milestone! Vitalgen closed its Angel funding round  
(Shanghai, China, June 23, 2020), Shanghai Vitalgen BioPharma Co., Ltd. Closed its Angel funding round. This round is led by IDG, with participation from Apricot Capital.  
123